Inhibitor Therapeutics, Inc. (INTI)

Inhibitor Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	8.84	11.95	0.03	0.08	0.8
Cash & Cash Equivalents	8.84	11.95	0.03	0.08	0.8
Cash Growth	-26.03%	38923.13%	-59.20%	-90.66%	-27.50%
Other Current Assets	0.11	0.02	0.03	0.03	0.04
Total Current Assets	8.95	11.98	0.06	0.11	0.85
Other Long-Term Assets	0	0	0	0.02	0.05
Total Long-Term Assets	0	0	0	0.02	0.05
Total Assets	8.95	11.98	0.06	0.13	0.9
Accounts Payable	0.03	0.15	0.28	0.27	0.32
Deferred Revenue	3	3	0.12	0.1	3
Current Debt	-3	0.41	0.23	0.03	-3
Other Current Liabilities	0.63	-2.88	0.05	0.03	0.12
Total Current Liabilities	0.67	0.68	0.68	0.43	0.43
Long-Term Debt	0	0	0	0.07	0
Other Long-Term Liabilities	3	3	3	3	3
Total Long-Term Liabilities	3	3	3	3.07	3
Total Liabilities	3.67	3.68	3.68	3.49	3.43
Total Debt	0	0.41	0.23	0.1	0
Debt Growth	-	77.92%	139.13%	-	-
Common Stock	0.02	0.02	0.04	0.04	0.04
Retained Earnings	-48.78	-45.75	-57.67	-57.17	-55.91
Comprehensive Income	0	-0	0	0	-0
Shareholders' Equity	5.28	8.3	-3.62	-3.36	-2.53
Total Liabilities and Equity	8.95	11.98	0.06	0.13	0.9
Net Cash / Debt	8.84	11.54	-0.2	-0.02	0.8
Net Cash / Debt Growth	-23.40%	-	-	-	-27.50%
Net Cash Per Share	0.05	0.03	-0.00	-0.00	0.00
Working Capital	8.28	11.3	-0.62	-0.32	0.42
Book Value Per Share	0.03	0.02	-0.01	-0.01	-0.01

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.